Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

Abstract

The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00279045 [ClinicalTrials.gov].).